Immunotherapy duo before liver surgery shows promise against cancer
NCT ID NCT03682276
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study focuses on safety and whether the treatment delays surgery or causes side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab and Nivolumab (immunotherapies)
What this could lead to
If successful, this approach could shrink liver tumors before surgery, potentially improving long-term outcomes for patients with hepatocellular carcinoma.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. Immunotherapies can cause serious side effects, including immune system overactivation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Imperial College Healthcare NHS Trust
London, Greater London, W12 0HS, United Kingdom